14191-90-3 Usage
Description
L-Norarginine, an Arginine (A769500) homolog, is an organic compound that plays a significant role in the synthesis of various derivatives and peptides. It is structurally similar to Arginine, a naturally occurring amino acid, and is characterized by the presence of a guanidine functional group.
Uses
Used in Pharmaceutical Industry:
L-Norarginine is used as a building block for the synthesis of derivatives and peptides of α-amino-β-guanidinopropionic acid and α-amino-γ-guanidinobutyric acid. These synthesized compounds have potential applications in the development of new drugs and therapeutic agents, making L-Norarginine a valuable component in the pharmaceutical industry.
Used in Research and Development:
In the field of research and development, L-Norarginine serves as an essential compound for the synthesis of novel peptides and derivatives. Its unique structure allows scientists to explore new avenues in drug discovery and design, potentially leading to the development of innovative treatments for various diseases and conditions.
Used in Biochemical Studies:
L-Norarginine is also utilized in biochemical studies to understand the role of Arginine and its analogs in various biological processes. By studying the properties and interactions of L-Norarginine, researchers can gain insights into the mechanisms of Arginine-related enzymes and proteins, which can be crucial for the development of targeted therapies and diagnostic tools.
Check Digit Verification of cas no
The CAS Registry Mumber 14191-90-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,1,9 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 14191-90:
(7*1)+(6*4)+(5*1)+(4*9)+(3*1)+(2*9)+(1*0)=93
93 % 10 = 3
So 14191-90-3 is a valid CAS Registry Number.
InChI:InChI=1/C5H12N4O2/c6-4(5(10)11)1-2-8-3-9-7/h3-4H,1-2,6-7H2,(H,8,9)(H,10,11)
14191-90-3Relevant articles and documents
Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase
Rossiter, Sharon,Smith, Caroline L.,Malaki, Mohammed,Nandi, Manasi,Gill, Herpreet,Leiper, James M.,Vallance, Patrick,Selwood, David L.
, p. 4670 - 4678 (2005)
The enzyme DDAH metabolizes methylarginines that are inhibitors of nitric oxide synthase (NOS). Substrate-based inhibitors of mammalian DDAH have been synthesized, with optimization to give selective inhibition of DDAH with no significant direct effect on NOSs. These are the first examples of reversible DDAH inhibitors with significant activity and selectivity. In vivo administration increases plasma ADMA levels, giving proof of concept that these inhibitors can be used to probe the physiological effects of DDAH inhibition, with potential for pharmaceutical use of DDAH inhibitors in diseases where excess NO production is implicated.
